- Home
- EPSM vs RFL Comparison
EPSM vs RFL Comparison
Compare EPSM & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EPSM | RFL |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6M | 63.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | EPSM | RFL |
|---|---|---|
| Price | $1.38 | $1.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.4K | ★ 46.7K |
| Earning Date | 05-24-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.04 | $1.12 |
| 52 Week High | $155.00 | $3.19 |
Technical Indicators
Market Signals| Indicator | EPSM | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 46.48 |
| Support Level | $1.31 | $1.15 |
| Resistance Level | $1.69 | $1.59 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 24.87 | 21.21 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.